Loading...
24 diet COVID-19 controlled studies
https://c19early.org/dtmeta.html
0
0.25
0.5
0.75
1
1.25
1.5
1.75
2+
Mahto 20%
0.80 [0.49-1.21]
IgG+
23/206
70/483
Improvement, RR [CI] Treatment Control Naushin 40%
0.60 [0.50-0.71]
seropositive
n/a
n/a
Kim 72%
0.28 [0.10-0.82]
m/s case
41 (n)
527 (n)
Kim 59%
0.41 [0.16-0.99]
m/s case
46 (n)
522 (n)
Kim 19%
0.81 [0.56-1.15]
cases
41 (n)
527 (n)
Kim 23%
0.77 [0.55-1.08]
cases
46 (n)
522 (n)
Merino 41%
0.59 [0.47-0.74]
severe case
148,142 (n)
148,143 (n)
Merino 18%
0.82 [0.78-0.86]
cases
148,142 (n)
148,143 (n)
Merino 9%
0.91 [0.88-0.94]
cases
148,142 (n)
148,143 (n)
Moludi 92%
0.08 [0.05-0.19]
cases
n/a
n/a
Ahmadi -3%
1.03 [0.77-1.39]
death
185/206,286
62/75,264
Nguyen 15%
0.85 [0.75-0.96]
symp. case
345/1,054
433/1,082
Yamamoto 66%
0.34 [0.13-0.85]
cases
4/20
19/32
Magaña 53%
0.47 [0.22-0.99]
death
58 (n)
31 (n)
Jagielski 82%
0.18 [0.04-0.65]
cases
4/40
9/20
Perez-Araluce 78%
0.22 [0.03-1.77]
severe case
1/1,103
10/3,300
Perez-Araluce 15%
0.85 [0.62-1.15]
symp. case
52/1,103
214/3,300
Perez-Araluce 20%
0.80 [0.60-1.07]
cases
58/1,103
248/3,300
Firoozi 65%
0.35 [0.28-0.43]
cases
case control
per unit E-DII change Hou 72%
0.28 [0.04-1.95]
severe case
1/22
78/487
Hou 11%
0.89 [0.58-1.36]
m/s case
11/22
273/487
Hou 74%
0.26 [0.10-0.67]
severe case
0/9
47/127
Hou 35%
0.65 [0.43-0.99]
m/s case
5/9
108/127
Zargarzadeh 77%
0.23 [0.11-0.50]
severe case
89 (n)
80 (n)
Yue 19%
0.81 [0.69-0.94]
cases
n/a
n/a
Yue 21%
0.79 [0.67-0.94]
cases
n/a
n/a
Yue 29%
0.71 [0.61-0.83]
cases
n/a
n/a
Yue 12%
0.88 [0.76-1.02]
cases
n/a
n/a
Zhou 16%
0.84 [0.78-0.91]
cases
1,321/10,254
1,935/10,253
Ebrahimzadeh 69%
0.31 [0.14-0.68]
severe case
n/a
n/a
Ebrahimzadeh 56%
0.44 [0.18-1.06]
hosp.
n/a
n/a
Ebrahimzadeh 68%
0.32 [0.15-0.68]
no recov.
n/a
n/a
Tadbir Vajargah 67%
0.33 [0.16-0.69]
severe case
83 (n)
83 (n)
Tadbir Vajargah 72%
0.28 [0.14-0.58]
severe case
83 (n)
83 (n)
Tadbir Vajargah 75%
0.25 [0.12-0.53]
severe case
83 (n)
83 (n)
Reis 75%
0.25 [0.12-0.52]
hosp.
17/380
21/166
Zhao 24%
0.76 [0.53-1.09]
death
39,230 (n)
39,231 (n)
Zhao 30%
0.70 [0.50-0.99]
death
39,230 (n)
39,231 (n)
Zhao 28%
0.72 [0.60-0.86]
severe case
39,230 (n)
39,231 (n)
Zhao 29%
0.71 [0.60-0.85]
severe case
39,230 (n)
39,231 (n)
Zhao 15%
0.85 [0.81-0.91]
cases
39,230 (n)
39,231 (n)
Zhao 9%
0.91 [0.85-0.96]
cases
39,230 (n)
39,231 (n)
Mohajeri 25%
0.75 [0.63-0.88]
progression
62/105
392/495
Mohajeri 51%
0.49 [0.40-0.60]
progression
50/105
482/495
Mohajeri 70%
0.30 [0.21-0.43]
progression
23/105
365/495
Mohajeri -10%
1.10 [1.03-1.17]
progression
98/105
421/495
Mohajeri 53%
0.47 [0.36-0.61]
progression
38/105
380/495
Mohajeri 26%
0.74 [0.58-0.94]
progression
44/105
280/495
Wang 9%
0.91 [0.72-1.14]
PASC
124/318
218/480
LONG COVID
Wang 49%
0.51 [0.33-0.78]
PASC
188 (n)
66 (n)
LONG COVID
Zamanian 81%
0.19 [0.07-0.55]
hosp.
case control
Barania Adabi 99%
0.01 [0.00-0.21]
ICU
0/125
37/125
Barania Adabi 98%
0.02 [0.00-0.31]
ICU
0/125
26/125
Diet COVID-19 outcomes c19 early.org/dt May 2023Favors healthy diet
Favors control
Please send us corrections, updates, or comments. Vaccines and
treatments are complementary. All practical, effective, and safe means should
be used based on risk/benefit analysis. No treatment, vaccine, or intervention
is 100% available and effective for all current and future variants. We do not
provide medical advice. Before taking any medication, consult a qualified
physician who can provide personalized advice and details of risks and
benefits based on your medical history and situation.
FLCCC and
WCH
provide treatment protocols.
Submit
